Description
Tigecycline-d
9 is intended for use as an internal standard for the quantification of tigecycline by GC- or LC-MS. Tigecycline is a broad-spectrum glycylcycline antibiotic that binds to the bacterial 30S ribosome, blocking the entry of transfer RNA, which halts protein synthesis and inhibits bacterial growth.
1 It is active against a panel of 1,924 European clinical bacterial isolates including
S. aureus,
S. epidermidis,
S. pneumoniae,
E. faecalis,
E. faecium,
E. coli,
K. pneumoniae,
P. aeruginosa, and
P. mirabilis strains (MICs = <1-32 μg/ml).
2 In vivo, tigecycline (6.25 mg/kg twice daily for 5 days) decreases levels of
C. difficile cytotoxin activity and spore formation in cecum and colon in a mouse model of
C. difficile infection.
3 Formulations containing tigecycline have been used in the treatment of a variety of bacterial infections.
References
1. Greer, N.D.
Tigecycline (Tygacil): The first in the glycylcycline class of antibiotics Proc. (Bayl. Univ. Med. Cent.) 19(2),155-161(2006).
2. Milatovic, D., Schmitz, F.J., Verhoef, J., et al.
Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates Antimicrob. Agents Chemother. 47(1),400-404(2003).
3. Theriot, C.M., Schumacher, C.A., Bassis, C.M., et al.
Effects of tigecycline and vancomycin administration on established Clostridium difficile infection Antimicrob. Agents Chemother. 59(3),1596-1604(2015).
